Ceglution XR is a mood stabilizer used for managing the significant emotional and behavioral instability associated with Bipolar Disorder (manic-depressive illness). Its therapeutic benefit is delivered across both acute crises and long-term stabilization, contributing to the maintenance of functional stability.

This medication is used to treat and prevent episodes of mania and is considered relevant in long-term treatment. It is commonly used across conditions characterized by episodic or fluctuating symptom patterns, including acute manic episodes, mixed episodes, and as an adjunctive agent for treatment-resistant depression.

Therapeutic Focus and Benefits

Ceglution XR is applied in clinical settings marked by heightened patient distress to address symptoms related to motor hyperactivity, aggressive behaviors, extreme irritability, and poor judgment. The core benefit is to provide symptomatic relief by assisting with the stabilization of mood and managing these intense, challenging behavioral patterns.

“This ongoing use provides essential support that may help patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Extreme Mood Shifts Ceglution XR helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms, and assists with maintaining functional stability.

Regulatory References

1. NIH MedlinePlus overview

The eligibility for Ceglution XR (Lithium Carbonate Extended-Release) is strictly governed by regulatory bodies based on specific health and physiological constraints.

Contraindicated Populations

Use of the medicine is contraindicated in populations with severe renal impairment, as the drug is primarily excreted by the kidneys, creating a high risk of toxicity. It is also prohibited in patients with Brugada syndrome or a family history of the disorder, and those with significant cardiovascular disease associated with rhythm disorder. Absolute exclusions extend to severe dehydration, sodium depletion, and untreated hypothyroidism.

Age and Conditional Use

Ceglution XR is approved for adults and for adolescents 12 years of age and older. The extended-release formulation is not recommended for children younger than 12 years because safety and effectiveness have not been established. Older adults may exhibit signs of toxicity at lower concentrations and require caution. Use during breastfeeding is contraindicated. During pregnancy, use is restricted and permitted only when the potential benefit outweighs the potential risk of fetal harm, such as cardiac anomalies. Mild to moderate renal impairment is an additional restriction that requires careful monitoring.

The interaction profile for Ceglution XR (Lithium Carbonate) is governed by substances that affect its renal clearance or produce additive neurological effects. The official regulatory documentation establishes specific interaction classifications.

Interacting Substance Category	Interaction Outcome (Officially Documented)
Renal Clearance-Reducing Agents (e.g., NSAIDs, ACE Inhibitors, Diuretics)	Increases plasma concentration of lithium, carrying a high risk of toxicity.
Serotonergic Agents (e.g., SSRIs, St. John's Wort)	Increases the documented risk of Serotonin Syndrome when co-administered.
Neuroleptics (e.g., Haloperidol)	Associated with the documented risk of Encephalopathic Syndrome.
Xanthine Derivatives (e.g., Caffeine, Theophylline)	Decreases serum lithium concentrations by increasing its urinary excretion.

The co-administration of Diuretics and ACE Inhibitors is generally not recommended in regulatory labeling due to the potential for significantly elevated lithium levels resulting from reduced renal clearance. NSAIDs, including Indomethacin and Piroxicam, are formally documented to substantially increase steady-state plasma lithium concentrations. Interactions with food and supplements are restricted to those affecting the body's sodium and fluid balance; a low-salt diet is formally documented to increase the risk of lithium accumulation. The risk of interaction-related toxicity is officially heightened in populations with impaired renal function or conditions causing dehydration or sodium depletion.

The mechanism of action of Ceglution XR centers on a multi-target approach to the modulation of nerve cell activity across the central nervous system (CNS). .

---

Modulating Intracellular Signaling (The Attenuation Effect)

This domain focuses on the active component's ability to act as an uncompetitive inhibitor of the enzyme Inositol Monophosphatase (IMPase). By targeting this enzyme, the drug disrupts the Inositol second messenger system, leading to a functional reduction in excitatory signaling within certain neural circuits. This molecular cascade results in the attenuation of neuronal hyperexcitability, supporting a state of reduced electrical volatility in the brain.

---

Influencing Neuronal Resilience and Plasticity

The active component also engages mechanisms that influence neuronal integrity by directly inhibiting the enzyme Glycogen Synthase Kinase-3 Beta (GSK-3β). This inhibition activates pathways critical for cell survival and neuroplasticity. The resulting effect contributes to cellular resilience and the regulation of chronic neuronal signaling, modulating the physiological response to cellular stress.

---

Adjusting Ion and Neurotransmitter Balance

This mechanism involves the Lithium ion (Li^+) subtly competing with the native Sodium ion (Na^+) to modulate the firing threshold of nerve cells. Simultaneously, the drug promotes an increase in inhibitory (GABA) function while decreasing excitatory (Glutamate) signaling. This action adjusts the overall electrochemical and chemical environment of the CNS, resulting in a modulated physiological state.

How to Use Ceglution XR

Ceglution XR is a prescription-only medicine administered via the oral route as a prolonged-release tablet. The instructions for use are intended for the controlled delivery of the active substance.

---

Official Administration Guidelines

Instruction	Detail
Route of Administration	Oral route only.
Dosing Schedule	Acute Stabilization: Typically titrated up to a total daily intake of 1800 mg. Maintenance: Standard daily range is 900 mg to 1200 mg.
Frequency	Used on a daily basis, often in divided doses initially, with the prolonged-release formulation allowing for potential once-daily administration during maintenance.
Physical Handling	The prolonged-release tablet must be swallowed whole. The tablet must not be crushed, chewed, or divided as this compromises the extended-release design.
Administration Context	May be taken with food. Treatment is contingent upon frequent and accurate serum concentration monitoring to guide dose adjustments.

---

Population-Specific Use and Procedural Structure

For older adults, instructions involve starting at the low end of the dosage range and titrating the dose slowly due to changes in renal function. Use in children under 12 years is generally not established.

The treatment protocol involves commencing with the appropriate initial dose, followed by serum level checks to achieve the desired concentration, and then transitioning to a long-term maintenance dose. Patients are also expected to maintain adequate daily fluid and salt intake as part of the clinical protocol.

This structured approach, defined by specific dosing and monitoring requirements, characterizes the standardized use of the medicine across both acute and long-term treatment phases.

Research Evidence / Overview of Studies for Ceglution XR

---

Evidence for Long-Term Mood Stabilization and Anti-Relapse

Research exploring the long-term use of the active substance in Ceglution XR has been studied primarily in the context of maintenance treatment for Bipolar Disorder. Studies conducted during periods of increased symptom activity include randomized controlled trials (RCTs) that follow patients over extended time intervals. These trials were designed to observe how symptom patterns evolved in the study populations over the course of several years.

The main outcomes related to systemic or functional imbalance that researchers examined were the frequency and rate of a new manic, depressive, or mixed episode recurrence, along with the patient’s overall hospitalization rates. Studies reported a calculated difference in the rate of recurrence between the groups observed in the trials. Research describes variability in the findings, particularly in studies examining the prevention of depressive episodes.

What remains uncertain is how the research findings vary across all forms of Bipolar Disorder, as results apply primarily to the populations studied in the pivotal RCTs. Data are still emerging for certain complex conditions characterized by fluctuating or episodic manifestations, such as rapid-cycling presentations, which may limit the applicability of the findings.

---

Evidence for Managing Acute Manic and Mixed Episodes

The medicine was studied for its use in conditions involving periods of heightened symptoms, specifically during acute manic or mixed episodes. Research explored short-term symptom changes using RCTs where the medicine was compared to an inactive substance or other established treatments. These trials assessed symptom intensity or variability over a defined time interval, typically approx 3 to 6 weeks.

Studies monitored outcomes capturing phases of heightened symptom activity, which included measurements related to physical discomfort and patient-reported outcomes describing perceived discomfort. Research highlights changes measured during the study period, research explored outcomes related to changes in the severity of manic symptoms (e.g., hyperactivity, irritability) as assessed by clinical rating scales. These findings describe how symptoms were measured during the short treatment period.

Because follow-up durations were limited, these studies provide limited insight into the sustained mood stability or functional status outcomes needed after the immediate acute crisis resolves. Sample sizes were modest in some earlier studies, and evidence derived from settings with varying symptom burdens does not fully account for all patients who may experience acute episodes in the real world.

Key Studies & References Bipolar disorder: assessment and management (NICE Guideline CG185)

Common questions about Ceglution XR (FAQ)

---

Q: Does Ceglution XR interact with alcohol consumption?

Regulatory information indicates that central nervous system effects, such as confusion or dizziness, are possible side effects of the medicine. More importantly, dehydration and changes in fluid or sodium balance—which can be caused by alcohol—are known to significantly increase the risk of lithium toxicity. The official product information contains a full list of warnings and precautions.

---

Q: How does the extended-release mechanism affect the potential for side effects?

The extended-release formulation is specifically designed for a controlled, slower release of the active substance into the body. The controlled-release design helps maintain stable drug levels. This stable concentration is intended to reduce the risk of certain side effects that are associated with high peak concentrations in the blood.

---

Q: What were the main criteria for participants in the clinical trials of Ceglution XR?

Clinical studies have examined patient populations primarily in the context of manic episodes and maintenance treatment to help prevent recurrence in Bipolar Disorder. Specific health conditions that are listed as contraindications in the official label served as exclusions for study participation.

---

Q: What is the difference between the immediate-release and the extended-release versions of the medicine's side effect profile?

The stable blood levels achieved by the extended-release (XR) form are a key design feature. This formulation is intended to minimize certain side effects that are linked to the high peak drug concentrations experienced with the immediate-release version, while the potential for long-term effects remains similar.

---

Q: How long does it usually take for the effects of Ceglution XR to be noticeable?

The extended-release tablet generally reaches its peak concentration in the blood within 4 to 12 hours after administration. However, the full therapeutic effect for mood stabilization often requires a build-up period and may take several weeks to fully establish.

---

Q: Are there different strengths of the Ceglution XR medicine available?

Yes, official dosage form information confirms that the extended-release tablets are available in multiple strengths, which commonly include 300 mg and 450 mg.

---

Q: Does Ceglution XR affect the ability to drive or operate machinery?

Official warnings state that this medicine may impair mental and physical abilities, causing drowsiness, dizziness, or blurred vision. Regulatory warnings advise that patients should not operate vehicles or heavy machinery until they are aware of the medicine's effects on their own abilities.

---

Q: Can Ceglution XR cause unexpected weight changes?

Adverse reaction reporting indicates that weight gain is a potential side effect reported with the use of this medicine.

---

Q: What should be known about the discontinuation of Ceglution XR treatment?

Regulatory documents state that abrupt discontinuation of treatment should be avoided. Official guidance indicates that if treatment discontinuation is planned, the dosage is typically reduced gradually over time to help minimize the risk of symptom recurrence.

---

Q: Is Ceglution XR recommended for use by itself or only as a combination therapy?

The medicine is officially indicated for the treatment of acute manic episodes and for long-term maintenance therapy in Bipolar Disorder. Because it is indicated for both the treatment of acute episodes and for long-term maintenance, its use may include it being administered alone or as part of a combination regimen.

---

Q: Does the medicine have any known effects on appetite?

Adverse reaction reporting has included loss of appetite (anorexia). This symptom has been associated with early signs of potential toxicity, which is a condition requiring urgent professional evaluation.

---

Q: What information is available about using Ceglution XR in patients with diabetes?

The medicine can affect blood sugar levels and may potentially induce a condition called nephrogenic diabetes insipidus (a condition characterized by frequent urination and intense thirst). Due to these potential effects, close monitoring of blood glucose is often required for patients with pre-existing diabetes.

---

Q: What is the described risk of allergic reactions to Ceglution XR?

The official product information indicates that the medicine is contraindicated (meaning its use is prohibited) in patients with a known hypersensitivity or allergy to any of its components.

---

Q: Are there any known effects of Ceglution XR on liver function?

The medicine is excreted primarily by the kidneys, not the liver. However, the occurrence of elevated serum enzymes (which can include liver enzymes) has been reported in rare cases, particularly when the drug is co-administered with neuroleptic drugs.

---

Q: Can people with a history of seizures take Ceglution XR?

The medicine has documented effects on the central nervous system. Due to the potential for neurotoxicity, which can involve severe neurological signs, regulatory documents suggest that patients with pre-existing central nervous system impairment may require close monitoring.

---

Q: What happens if I forget a dose of Ceglution XR?

Official instructions provide guidance on the appropriate procedure for a missed dose, typically advising patients to avoid taking a double dose. This specific guidance is detailed in the official prescribing information.

---

Q: Does taking Ceglution XR cause any changes related to sleep or insomnia?

Adverse reaction reporting indicates the medicine can cause certain central nervous system effects. Symptoms such as drowsiness, lethargy, and general confusion are listed, which may signal that sleep and wakefulness patterns can be affected.

---

Q: Is there a liquid form available for Ceglution XR?

Regulatory information confirms that while Ceglution XR is the extended-release tablet form, the active ingredient (lithium carbonate) is also available in an oral solution (liquid) form.

How to Store and Dispose of Ceglution XR?

Ceglution XR (lithium carbonate extended-release tablets) must be stored and disposed of according to official regulatory requirements to maintain product integrity and ensure safety.

Storage Requirements

The medicine must be stored at Controlled Room Temperature (CRT), defined as 59^circ to 86^circF (15^circ to 30^circC). The container must provide protection from moisture and be tight and child-resistant. It is mandatory to keep the medicine out of the reach of children.

Disposal Instructions

Official guidance recommends using community drug take-back programs for unused or expired tablets. If a take-back program is unavailable, the product may be disposed of in household trash by mixing the tablets with an undesirable substance, sealing the mixture in a container, and discarding it. Patients should scratch out all identifying information on the label before disposal.